NewsBenzingaAnixa Biosciences Announces Second Patient Has Been Treated In Fifth Cohort Of Its Ongoing Phase 1, Dose-Escalating, Clinical Trial Evaluating FSHR-Targeted CAR-T Therapy For Recurrent Ovarian Cancer Anixa Biosciences Announces Second Patient Has Been Treated In Fifth Cohort Of Its Ongoing Phase 1, Dose-Escalating, Clinical Trial Evaluating FSHR-Targeted CAR-T Therapy For Recurrent Ovarian Cancer Benzinga 2026.10.01 12:40 (GMT+0) Open on Benzinga Other news If You Invested $1000 In HSBC Holdings Stock 5 Years Ago, You Would Have This Much Today Li Auto (LI) Deliveries Fall Even as Li L6 Tops 10,000 in September Evercore ISI Group Maintains Underperform on Zions Bancorp, Lowers Price Target to $64 Evercore ISI Group Maintains Outperform on Wells Fargo, Lowers Price Target to $90 Oracle Stock Is Falling: What's Going On? Evercore ISI Group Maintains Outperform on U.S. Bancorp, Lowers Price Target to $65
